NCT01424813View on ClinicalTrials.gov

A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

November 30, 2013

Conditions
Asthma
Interventions
DRUG

Placebo MDPI

Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.

DRUG

Albuterol MDPI

Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.

Trial Locations (38)

Unknown

Teva Investigational Site 10077, Birmingham

Teva Investigational Site 10079, Phoenix

Teva Investigational Site 10569, Costa Mesa

Teva Investigational Site 10053, Fountain Valley

Teva Investigational Site 10065, Huntington Beach

Teva Investigational Site 10572, Huntington Beach

Teva Investigational Site 10075, Los Angeles

Teva Investigational Site 10061, Roseville

Teva Investigational Site 10066, San Diego

Teva Investigational Site 10068, Denver

Teva Investigational Site 10069, Denver

Teva Investigational Site 10058, Miami

Teva Investigational Site 10060, Miami

Teva Investigational Site 10064, Ormond Beach

Teva Investigational Site 10071, Savannah

Teva Investigational Site 10073, Wichita

Teva Investigational Site 10070, Owensboro

Teva Investigational Site 10063, Bethesda

Teva Investigational Site 10571, Gaithersburg

Teva Investigational Site 10067, Wheaton

Teva Investigational Site 10072, St Louis

Teva Investigational Site 10050, Missoula

Teva Investigational Site 10057, Raleigh

Teva Investigational Site 10051, Cincinnati

Teva Investigational Site 10078, Sylvania

Teva Investigational Site 10054, Oklahoma City

Teva Investigational Site 10568, Oklahoma City

Teva Investigational Site 10055, Tulsa

Teva Investigational Site 10056, Medford

Teva Investigational Site 10076, Medford

Teva Investigational Site 10684, Charleston

Teva Investigational Site 10570, Spartanburg

Teva Investigational Site 10049, Live Oak

Teva Investigational Site 10052, San Antonio

Teva Investigational Site 10685, Waco

Teva Investigational Site 10059, Fairfax

Teva Investigational Site 10074, Puyallup

Teva Investigational Site 10062, Tacoma

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT01424813 - A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma | Biotech Hunter | Biotech Hunter